-
Uncategorized2 months ago
Cochrane review dismissing amyloid drugs draws immediate backlash
A new report trying to settle a decades-old debate about Alzheimer’s disease has reached a dramatic conclusion: Antibody drugs that target sticky amyloid beta proteins in...
-
Uncategorized2 months agoFDA moves toward easing restrictions on certain peptides
The agency’s decision to hold an advisory committee meeting on the topic comes after HHS Secretary Robert F. Kennedy Jr. told podcaster Joe Rogan he’s a...
-
Uncategorized2 months agoLilly’s new obesity pill passes heart safety test in diabetes
The findings, which come amid FDA scrutiny of Foundayo’s safety, will enable Lilly to seek a new clearance in diabetes. Read More
-
Uncategorized2 months agoAsgard Therapeutics appoints Dr Wolfram Brugger as CMO
Biotechnology company Asgard Therapeutics has appointed Dr Wolfram Brugger as Chief Medical Officer. Brugger, who has been involved in more than 130 Phase I to III clinical...
-
Uncategorized2 months ago
MeiraGTx buys back gene therapy from J&J; Storm brings in $56M Series C
MeiraGTx buys back gene therapy from J&J; Storm brings in $56M Series C
-
Uncategorized2 months ago
Landmark Pancreatic Cancer Trial Highlights Promise of RAS-Targeting Daraxonrasib
Earlier this week, Revolution Medicines reported positive results from a global Phase III trial of its RAS‑targeting inhibitor daraxonrasib (RMC-6236) in metastatic pancreatic ductal adenocarcinoma (PDAC)....
-
Uncategorized2 months ago
Blurring the lines of healthcare AI
If you asked me a year ago to break down the different areas of healthcare AI we’re covering, it might’ve looked like scribes, clinical decision support...
-
Uncategorized2 months ago
MeiraGTx, spying hope in a failed trial, buys back eye disease gene therapy from J&J
J&J will hand over the rights to bota-vec for $25 million upfront, clearing MeiraGTx to seek regulatory approvals in the U.S. and EU in 2027.
-
Uncategorized2 months ago
Using versus selling lucrative PRVs: Moderna’s cautionary tale
Using versus selling lucrative PRVs: Moderna's cautionary tale
-
Uncategorized2 months ago
MSF says Gilead’s lenacapavir supply ‘not nearly enough’; PolyPeptide’s strategic review
Plus, news about Grand River, syringe stockpiling in South Korea and Cellares: 💉 MSF criticizes Gilead’s lenacapavir supply: Gilead is expanding supply of the HIV prevention...
Amgen shores up Tavneos’ FDA defense with Duke data analysis
